Agendia is a leading molecular diagnostics company focused on improving the quality of life for cancer patients by developing genomic tests to support physicians in making complex treatment decisions, whilst reducing costs to the healthcare system.
Founded in 2003 with facilities in Amsterdam, the Netherlands and Irvine, CA, Agendia’s suite of gene expression-based breast cancer tests analyze a patient’s tumor, providing their physician with unique genomic insight to personalize treatment.
For the latest news and to learn more about Agendia, our team and our MammaPrint and BluePrint tests, please visit our corporate site at www.agendia.com
